- Home
- EXFY vs PBYI Comparison
EXFY vs PBYI Comparison
Compare EXFY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- PBYI
- Stock Information
- Founded
- EXFY 2008
- PBYI 2010
- Country
- EXFY United States
- PBYI United States
- Employees
- EXFY N/A
- PBYI N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- PBYI Health Care
- Exchange
- EXFY Nasdaq
- PBYI Nasdaq
- Market Cap
- EXFY 150.3M
- PBYI 126.5M
- IPO Year
- EXFY 2021
- PBYI N/A
- Fundamental
- Price
- EXFY $2.93
- PBYI $3.03
- Analyst Decision
- EXFY Hold
- PBYI Strong Buy
- Analyst Count
- EXFY 5
- PBYI 1
- Target Price
- EXFY $2.63
- PBYI $7.00
- AVG Volume (30 Days)
- EXFY 682.8K
- PBYI 452.0K
- Earning Date
- EXFY 11-07-2024
- PBYI 11-07-2024
- Dividend Yield
- EXFY N/A
- PBYI N/A
- EPS Growth
- EXFY N/A
- PBYI 492.79
- EPS
- EXFY N/A
- PBYI 0.47
- Revenue
- EXFY $137,440,000.00
- PBYI $243,569,000.00
- Revenue This Year
- EXFY N/A
- PBYI N/A
- Revenue Next Year
- EXFY $7.39
- PBYI N/A
- P/E Ratio
- EXFY N/A
- PBYI $6.39
- Revenue Growth
- EXFY N/A
- PBYI 6.30
- 52 Week Low
- EXFY $1.24
- PBYI $2.23
- 52 Week High
- EXFY $3.00
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- EXFY 80.16
- PBYI 56.74
- Support Level
- EXFY $1.82
- PBYI $2.83
- Resistance Level
- EXFY $3.00
- PBYI $3.51
- Average True Range (ATR)
- EXFY 0.17
- PBYI 0.25
- MACD
- EXFY 0.13
- PBYI 0.01
- Stochastic Oscillator
- EXFY 85.71
- PBYI 48.15
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.